What Dalmatrol Plus Treats: Main Uses and Benefits

The primary therapeutic benefit of Dalmatrol Plus plays a role in managing symptoms related to physical discomfort in situations where patients experience pronounced discomfort and additional symptomatic support is needed. This combination is typically indicated for easing symptoms associated with moderate to severe acute pain.

Symptomatic Support and Relief

The medication is commonly used across conditions presenting with acute episodes and during phases when symptoms become more noticeable, including pain following minor surgical procedures and pain from acute injuries. It is considered relevant for easing symptoms associated with chronic lower back pain or osteoarthritis.

The combination is generally applied when symptoms related to physical discomfort are pronounced. It may assist in easing the overall symptom burden when supportive symptom management is appropriate, and contributes to improved comfort during periods of heightened symptoms. It supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Moderate to Severe Pain

Dalmatrol Plus is relevant in clinical settings that involve acute or unstable symptom patterns, often used during phases when symptoms become temporarily overwhelming. It is intended for use when appropriate, as it contributes to easing the overall symptom load.

Regulatory References

1. DailyMed (NIH) on Tramadol/Acetaminophen Tablets

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults and adolescents 12 years of age and older whose condition is assessed as requiring a combination of tramadol and acetaminophen.

Populations for whom use is not recommended (if applicable):

• Patients with severe renal impairment (creatinine clearance <10 mL/min) [Source 3.6].
• Women who are breastfeeding [Source 1.3].
• Patients over 75 years (due to potentially prolonged elimination) [Source 3.6].

Populations for whom use is contraindicated:

• Children younger than 12 years of age [Source 1.1].
• Children younger than 18 years of age for postoperative management following tonsillectomy and/or adenoidectomy [Source 1.1].
• Patients with significant respiratory depression or severe bronchial asthma in an unmonitored setting [Source 1.1].
• Patients with severe hepatic impairment or acute intoxication with alcohol, opioids, or hypnotics [Source 3.6].
• Patients receiving Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of their withdrawal [Source 3.6].

Condition-Specific Eligibility Rules

Condition Status	Eligibility Classification (Regulatory Wording)
Severe Hepatic Impairment	Contraindicated [Source 3.6]
Severe Renal Impairment	Not Recommended [Source 3.6]
Uncontrolled Epilepsy	Contraindicated [Source 3.6]
Pregnancy (Prolonged Use)	Can result in Neonatal Opioid Withdrawal Syndrome (NOWS); patient must be advised of this risk [Source 1.1]
CNS Trauma/Circulatory Shock	Avoid use (e.g., in patients with increased intracranial pressure or impaired consciousness) [Source 1.1]

Connection to the overall eligibility profile: Official regulatory documents define the eligibility profile for this medicine through multiple exclusion criteria. Absolute non-eligibility is established by contraindications related to age, pre-existing comorbidities (e.g., severe liver impairment), and concurrent medication use (MAOIs). Restricted or conditional eligibility is also formally defined for groups with organ compromise (e.g., severe renal impairment) and specific physiological states (pregnancy and lactation), setting strict population boundaries for its use.

Interactions with other medicines and products

Dalmatrol Plus is a fixed-dose combination of Acetaminophen and Tramadol Hydrochloride. Officially documented interactions are classified based on pharmacokinetic (metabolic) and pharmacodynamic effects, primarily related to the Tramadol component.

---

Contraindicated and High-Risk Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated; treatment must not be initiated within 14 days of discontinuing an MAOI. The co-administration of Dalmatrol Plus with other acetaminophen-containing products is also restricted to avoid exceeding the maximum daily dose for the acetaminophen component.

---

Drug-Drug Interactions

Interactions involving the Cytochrome P450 (CYP) enzymes alter Tramadol exposure. CYP2D6 inhibitors and CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole) may increase Tramadol plasma concentrations. Conversely, CYP3A4 inducers (e.g., Carbamazepine) may reduce the analgesic effect.

• Pharmacodynamic Interactions: Combining with other Central Nervous System (CNS) depressants (including alcohol) increases the risk of profound sedation. Concomitant use with Serotonergic Drugs (e.g., SSRIs, Triptans) is associated with an increased risk of Serotonin Syndrome and seizure. The combination with Coumarin derivatives (e.g., Warfarin) has been associated with changes in prothrombin time.

---

Food and Substance Interactions

Administration with food is officially noted to delay the time to peak plasma concentration (Tmax), but does not significantly affect the total absorption. The concurrent use of alcohol is specifically restricted due to enhanced CNS depression risk.

How Dalmatrol Plus Works

Dalmatrol Plus acts at a molecular level to influence regulatory dynamics within specific communication systems in the body. Its effect is highly targeted, focusing solely on the internal mechanics of cellular signaling.

Targeting Key Receptor and Enzyme Systems

The drug initiates its action by engaging directly with defined biological targets, primarily specific receptor or enzyme systems. This engagement is designed to rapidly modulate activity within these systems, providing a mechanism-driven adjustment of signal transduction at the cellular level.

Modulating Overactive Signaling Cascades

Following its molecular binding, Dalmatrol Plus works within well-characterized molecular cascades to influence the chain reaction of cellular messages. This mechanism is particularly relevant in systems involving heightened pathway activation, where the drug dampens excessive signaling and regulates the activity in specific physiological pathways.

Influencing Central and Peripheral Pathway Activity

By interfering with signaling dynamics, the drug results in changes to pathway activity within the targeted circuits. This alters specific physiological parameters by influencing the activity within central or peripheral communication routes, thereby modulating the downstream effects of overactive mediator activity on the body's systems.

Dalmatrol Plus is administered exclusively via the oral route as a fixed-dose combination tablet. The medication is designed for use on an as-needed (PRN) basis, adhering to a strict time-based frequency pattern.

The standard adult starting dose is typically two tablets, which corresponds to 75 mg of Tramadol Hydrochloride and 650 mg of Acetaminophen per administration. The dosing interval is not to be shorter than six hours between administrations, ensuring appropriate spacing between the active components. The total daily intake is not to exceed eight tablets over a 24-hour period.

For proper administration, the film-coated tablets are swallowed whole with sufficient liquid and are not to be crushed or chewed. The medicine may be taken without regard to food, meaning it can be administered with or without meals.

The medicine is generally indicated for short-term use, often specified as five days or less for acute pain management. Dosing adjustments are utilized for specific populations to manage elimination kinetics; for patients with severe renal impairment (creatinine clearance less than 30 mL/min), the dosing interval is extended to 12 hours. An extended interval may also be applicable for patients over 75 years of age.

Research Evidence / Overview of Studies for Dalmatrol Plus

---

Evidence from Clinical Trials for Acute Pain Relief

Researchers have conducted short-term Randomized Controlled Trials (RCTs) and systematic reviews that studied the combination in patients with moderate to severe acute pain, such as pain following surgical or dental procedures. These trials monitored outcomes related to physical discomfort, including measures of perceived discomfort and the duration of observed change in symptom patterns.

Studies reported patterns in measured outcomes related to symptom change compared to an inactive substance (placebo). Findings describe patterns where the combination's measured outcomes were observed separately from those of the single-agent active ingredients used alone. However, follow-up durations were limited, meaning strategies for pain lasting more than 5 to 10 days are not well characterized. Comparative evidence against other non-combination analgesics is also limited.

Evidence from Clinical Trials for Chronic Pain Management

Intermediate-term clinical studies, including multicenter RCTs, were applied in research contexts involving fluctuating symptoms linked to conditions such as chronic lower back pain and pain from osteoarthritis. Research examined outcomes reflecting daily functioning or activity level, alongside measures of pain intensity.

Trials spanning up to three months reported a measured change in both pain intensity scores and physical function scales in the observed populations. Some systematic reviews described study findings that were mixed, noting only a modest measured shift in daily activity level in some cohorts. Data for long-term outcomes and the persistence of observed patterns beyond this intermediate period remain insufficient.

Evidence in Specific Populations and Limitations

Key clinical trials primarily involved general adult populations. Data for special populations, such as older adults, children, or pregnant individuals, are not well documented in the main body of research, and findings in these groups are often uncertain. The overall evidence quality varies across studies, and significant data gaps remain regarding sustained use and effects in diverse populations. These aspects remain areas of ongoing research.

Key Studies & References

1. DailyMed (NIH) on Tramadol/Acetaminophen Tablets

Common questions about Dalmatrol Plus (FAQ)

---

Q: Is Dalmatrol Plus an antibiotic or a steroid?

According to the official drug label, Dalmatrol Plus is a combination of two types of pain relievers: an opioid analgesic (Tramadol) and a non-opioid analgesic (Acetaminophen).

Regulatory documents confirm that the medication is not classified as an antibiotic or a steroid.

---

Q: Does Dalmatrol Plus treat the root cause or just the symptoms of the condition?

Official regulatory documents describe Dalmatrol Plus as indicated for the symptomatic treatment of pain, meaning it addresses the pain itself.

The way the drug works is by acting on the central nervous system to modulate how the body experiences pain signals, rather than treating the underlying cause of the condition.

---

Q: Is the brand-name Dalmatrol Plus different from its generic version?

Official information pertains to the drug’s active ingredients, Tramadol and Acetaminophen, and their fixed-dose combination.

The medication is available as both the brand-name drug and a generic drug containing the same active components. Regulatory standards indicate the generic version works the same way.

---

Q: What type of health conditions is Dalmatrol Plus officially indicated for?

The official product information states that Dalmatrol Plus is indicated for the management of acute pain that is moderate to severe and requires an opioid analgesic.

Treatment with this combination medicine is typically intended for short-term use, often specified as five days or less, as longer-term data is limited.

---

Q: Does taking Dalmatrol Plus usually lead to weight gain or weight loss?

Clinical studies summarized in the regulatory documents do not list weight gain or weight loss among the most common adverse reactions.

However, some trials have reported instances of loss of appetite (anorexia).

---

Q: What is the official procedure for reporting a side effect?

The official procedure for reporting side effects is handled by the national regulatory authority in your country.

For example, in the United States, this is done through the FDA MedWatch program, and in the UK through the Yellow Card Scheme.

---

Q: Does Dalmatrol Plus require any special safety monitoring or blood tests?

Official warnings indicate that Dalmatrol Plus requires careful monitoring, primarily due to the risk of Hepatotoxicity (liver damage) associated with the Acetaminophen component.

Official warnings advise caution for use in populations with pre-existing liver or kidney conditions.

---

Q: Is it possible to have an allergic reaction to Dalmatrol Plus?

Yes, the regulatory documents list allergic reactions (hypersensitivity) as a potential safety concern, although they are rare.

Official guidance emphasizes that allergic reactions are serious and require prompt medical attention.

---

Q: Does Dalmatrol Plus have an effect on a person's blood pressure?

Official product information indicates that the medication can cause effects on the cardiovascular system, including adverse reactions such as Palpitations (pounding heartbeat) and Tachycardia (fast heart rate).

A direct effect on routine blood pressure is not commonly specified in regulatory adverse event listings.

---

Q: Can individuals with existing heart conditions take Dalmatrol Plus?

Official labeling notes that the drug is associated with risks such as QT prolongation, which affects heart rhythm.

Official labeling specifies that individuals with pre-existing heart problems, such as heart failure or certain rhythm disorders, face higher risk.

---

Q: How quickly does Dalmatrol Plus start to work after the first use?

According to the official regulatory and pharmacokinetic data, the pain-relieving effects of the Tramadol component are generally observed to begin within one hour after the tablet is taken orally.

---

Q: How long does the effect of a single dose of Dalmatrol Plus last?

Official pharmacokinetic information indicates that the pain-reducing effects of a single dose of the Tramadol component typically last for approximately six hours.

The mandated six-hour minimum dosing interval is designed to ensure appropriate spacing between doses.

---

Q: Are the clinical studies about Dalmatrol Plus available for public review?

Regulatory bodies often require clinical trial data to be submitted and registered on official government-run databases like ClinicalTrials.gov.

This makes information about the studies publicly accessible through these regulatory mechanisms.

---

Q: Will Dalmatrol Plus interact with common over-the-counter pain relievers like ibuprofen?

Official documents restrict combining Dalmatrol Plus with other acetaminophen-containing products to prevent exceeding the maximum safe dose.

Careful consideration of the maximum acetaminophen dose and the risks associated with all combined medications is required.

---

Q: What are the official recommendations about taking Dalmatrol Plus with grapefruit products?

Regulatory guidance suggests that the consumption of grapefruit and grapefruit juice is generally avoided in patients taking certain opioids.

This is because grapefruit can affect the metabolism (breakdown) of the tramadol component, which may alter the drug's effects in the body.

---

Q: Why do some people in online reviews mention that Dalmatrol Plus helped with X condition that isn't its main use?

The official labeling defines the drug's approved use (acute pain) and its Limitations of Use based on scientific evidence.

Regulatory documents only rely on evidence from approved trials, and they do not comment on unverified personal reports or online reviews that discuss effects outside of the approved indications.

---

Q: Is Dalmatrol Plus prescribed for a condition other than the main use?

The official labeling describes the drug’s approved indication (acute pain) and the specific conditions for which it has been formally reviewed and authorized.

Any use outside of the conditions specifically listed on the label is considered unapproved use (often referred to as off-label). Regulatory guidance does not cover or recommend unapproved use.

---

Q: Is it considered a high-alert medication?

Yes, Dalmatrol Plus is generally categorized as a high-risk or high-alert medication.

Official regulatory documents include a Boxed Warning that highlights the serious risks associated with the drug, including potential for addiction, abuse, misuse, and fatal respiratory depression.

How to Store and Dispose of Dalmatrol Plus

Official regulatory guidelines strictly define the conditions for storing and disposing of Dalmatrol Plus (Tramadol/Acetaminophen) to maintain product integrity and prevent misuse.

Storage Requirements

Item	Regulatory Requirement
Temperature	Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature).
Protection	Keep in a tightly closed container, protected from freezing, moisture, and excessive heat or light.
Safety	Must be stored securely and out of the reach of children due to the risk of accidental opioid ingestion.

---

Disposal Instructions

Official disposal is specified for unused or expired tablets. Patients are instructed to either use a drug take-back program or flush the medication down the toilet immediately to prevent diversion and accidental exposure. Patients may also contact state-controlled substances authorities for proper disposal guidance.